EXHIBIT 99.2

10 x 20: The Path to $10 Billion in Product Sales by 2020 Flemming Ornskov, MD, MPH CEO James Bowling Interim CFO 1

The "SAFE HARBOR" Statement under the Private Securities Litigation Reform Act of 1995 Statements included in this announcement that are not historical facts are forward -looking statements. Forward -looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, that:* Shire's products may not be a commercial success;* revenues from ADDERALL XR[R] are subject to generic erosion and revenues from INTUNIV[R] will become subject to generic competition starting in December 2014;* the failure to obtain and maintain reimbursement, or an adequate level of reimbursement, by third-party payors in a timely manner for Shire's products may impact future revenues, financial condition and results of operations;* Shire conducts its own manufacturing operations for certain of its Rare Diseases products and is reliant on third party contractors to manufacture other products and to provide goods and services. Some of Shire's products or ingredients are only available from a single approved source for manufacture. Any disruption to the supply chain for any of Shire's products may result in the Shire being unable to continue marketing or developing a product or may result in Shire being unable to do so on a commercially viable basis for some period of time. * the development, approval and manufacturing of Shire's products is subject to extensive oversight by various regulatory agencies. Submission of an application for regulatory approval of any of our product candidates, such as our planned submission of a New Drug Application to the FDA for lifitegrast as a treatment for the signs and symptoms of dry eye disease in adults, may be delayed for any number of reasons and, once submitted, may be subjected to lengthy review and ultimately rejected. Any regulatory approvals or interventions associated with changes to manufacturing sites, ingredients or manufacturing processes could lead to significant delays, increase in operating costs, lost product sales, an interruption of research activities or the delay of new product launches;* the actions of certain customers could affect Shire's ability to sell or market products profitably. Fluctuations in buying or distribution patterns by such customers can adversely impact Shire's revenues, financial conditions or results of operations;* investigations or enforcement action by regulatory authorities or law enforcement agencies relating to Shire's activities in the highly regulated markets in which it operates may result in the distraction of senior management, significant legal costs and the payment of substantial compensation or fines;* adverse outcomes in legal matters and other disputes, including Shire's ability to enforce and defend patents and other intellectual property rights required for its business, could have a material adverse effect on Shire's revenues, financial condition or results of operations;* Shire faces intense competition for highly qualified personnel from other companies, academic institutions, government entities and other organizations. Shire is undergoing a corporate reorganization and the consequent uncertainty could adversely impact Shire's ability to attract and/or retain the highly skilled personnel needed for Shire to meet its strategic objectives;* failure to achieve Shire's strategic objectives with respect to the acquisition of ViroPharma Incorporated may adversely affect Shire's financial condition and results of operations; and other risks and uncertainties detailed from time to time in Shire's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K. 2

Basis of forecasts and targets The Shire forecasts and targets included in this announcement and the presentation are derived from Shire's Long Range Plan for 2014 to 2020 (the "LRP"), business papers produced to support the LRP and Shire papers subsequently produced as part of the business planning process. Shire produces a long range plan annually. The LRP was updated in September 2013 and was reviewed by the Board of Shire in October 2013. A revised LRP was developed to reflect the acquisition of ViroPharma, the disposal of DERMAGRAFT [R], the termination of the VYVANSE[R] Major Depressive Disorder program, 2013 full year reported financial results and other events in 2014. This revised LRP was reviewed by the Board of Shire most recently in June 2014. The forecast product sales targets for 2016 and 2020 in this announcement and the presentation are consistent with the LRP for the period from 2014 to 2020, which is at constant exchange rates, and reflects net sales for each product and key line extensions currently identified as in Phase III, Phase II and those in (or soon to enter) Phase I included in the LRP as launching before the end of 2020. The forecast product sales included in the LRP are risk-adjusted to reflect Shire's assessment of the individual probability of launch of products in development, and the probability of success in further life cycle management trials. Estimates for these probabilities are based on industry wide data for relevant clinical trials in the pharmaceutical industry at a similar stage of development. For each pharmaceutical product, there is a range of possible outcomes from clinical development, driven by a number of variables - including safety, efficacy and product labelling. In addition, if a product is approved, the effect of commercial factors including the patient population, the competitive environment, pricing and reimbursement is also uncertain. As a result, the actual net sales achieved by a product over its commercial life will be different, perhaps materially so, from the risk adjusted net sales figures in this announcement and the presentation and should be considered in this light. Peak year sales referred to in this announcement and the presentation are Shire management's estimates of the highest annual net sales for the relevant product. These peak year sales estimates are not risk-adjusted, and are made using customary pharmaceutical industry forecasting methods. Some of these peak year sales occur in years later than 2020, but these estimates are consistent with the plans and projections of the LRP period. Peak year sales may occur in different years for each product, depending on trial outcomes, launch dates, pricing assumptions and exclusivity periods, amongst other things. The aggregation of peak sales is the sum of peak year sales for each asset and not for one particular year. Peak year sales are net product sales at nominal values and are undiscounted. 2020 sales referred to in this announcement and the presentation for individual products are Shire management's estimates of the potential annual net sales for the relevant product. These estimates are not risk-adjusted, and are made using customary pharmaceutical industry forecasting methods. 3

10 x 20: We believe we can deliver substantially more value and build upon our leadership position in Rare Diseases We are executing our plan Shire has a history of double -digit growth and above-average returns New management dramatically transformed Shire over the last year This has led to a step change in growth, efficiency and innovation We have the platform and team to further enhance these trends We expect to achieve $10 billion in product sales by 2020 Potential upside to 10x20 from recent deals and future business development to drive long-term growth even before additional M&A and in-licensing 1 Product sales; Percent CAGR [GRAPHIC OMITTED] 1 Forecast growth includes Viropharma product sales (Viropharma was acquired by Shire in January 2014). Further potential upside to this 10x20 target includes the Lumena acquisition, the recently announced Fibrotech transaction and future M&A and licensing. Growth refers to compound annual product sales growth. 4

Shire has a history of generating double -digit growth and above-average shareholder returns [GRAPHIC OMITTED] Source: Company reports, S&P Capital IQ (McGraw Hill Financial) as of 19 June 2014 1 Product sales and Non-GAAP EBITDA are from continuing operations and exclude DERMAGRAFT which is treated as a discontinued operation following divestment in January 2014. 2 This is a Non-GAAP financial measure. The most directly comparable measure under U.S. GAAP is net income (2008: $156M; 2009: $492M; 2010: $588M; 2011: $865M; 2012: $745M; 2013: $665M). See slide 37 for a list of items excluded from the U.S. GAAP equivalent used to calculate this measure. 3 Median of peers including Alexion, Amgen, Biogen, Celgene and Gilead. 5

New management has created a platform to deliver sustainable growth and superior patient outcomes 10 x 20: Shire expects to achieve $10 billion in product sales by 2020 even before additional M&A and in-licensing [GRAPHIC OMITTED] 6

We made tremendous progress in the past year and will build upon our leadership position in Rare Diseases [GRAPHIC OMITTED] 1 Results exclude DERMAGRAFT which is treated as a discontinued operation following divestment in January 2014. On a total business basis in Q1 2013, including DERMAGRAFT, product sales growth was +1% and Non GAAP EBITDA margin was 34%. 2. Refers to Q1 2013 vs. Q1 2012. 3 As at 1 May 2014 4 Refers to Q1 2014 vs. Q1 2013 5 As at 2 May 2013 6 This is a Non-GAAP financial measure. The most directly comparable measure under U.S. GAAP is net income (Q1 2014: $230M or 18% of product sales; Q1 2013: $65M or 6% of product sales). See slide 37 for a list of items excluded from the U.S. GAAP equivalent used to calculate this measure. 7 Total shareholder return, including reinvestment of dividends, from 2 May 2013 to 19 June 2014 7

We have accelerated our top-line growth Management actions Improved Rare Diseases competitive performance Sharpened Neuroscience customer focus Achieved #1 position in 5-ASA market 2 Added ViroPharma, including Cinryze in Rare Diseases 1Q 2014 Product sales growth 1 [GRAPHIC OMITTED] 1 Product sales are from continuing operations, and exclude DERMAGRAFT which is treated as a discontinued operation following divestment in January 2014. 2 IMS NPA Weekly Date Reports for week ending 7 February 2014. 8

We simplified our structure Organizational transition [GRAPHIC OMITTED] Core components 4x commercially focused business units 1x integrated R&D organization 1x international infrastructure with presence in 50+ countries Streamlined supporting functions Increased operating leverage 9

which has led to a step change in efficiency Efficiency program Integrated R&D under a single leadership team Created a single, consolidated international structure Streamlined other corporate functions Halted programs that did not fit strategic or commercial criteria Divested DERMAGRAFT Significant increase in EBITDA margin 1,2 [GRAPHIC OMITTED] 1 Results exclude DERMAGRAFT which is treated as a discontinued operation following divestment in January 2014. 2 These are Non-GAAP financial measures. The most comparable measures under U.S. GAAP are cost of product sales as a percentage of product sales (1Q 2014: 18%; 1Q 2013: 13%), R&D as a percentage of product sales (1Q 2014: 28%; 1Q 2013: 20%) and SG&A as a percentage of product sales (1Q 2014: 33%; 1Q 2013: 36%). See slide 37 for a list of items excluded from the U.S. GAAP equivalents used to calculate the measures. 3 Excluding royalties and other revenues. 6 This is a Non-GAAP financial measure. The most directly comparable measure under U.S. GAAP is net income (Q1 2014: $230M or 18% of product sales; Q1 2013: $65M or 6% of product sales). See slide 37 for a list of items excluded from the U.S. GAAP equivalent used to calculate this measure 10

We materially improved our existing pipeline SHP465 [] Resubmitted SHP465 for high-growth ADHD adult segment ADHD [] Expect to launch in 1H15 ------------------------------------------------------------ [] Positive Phase 3 results LDX(1) [] APA presentation in May; plan to file NDA in 3Q14; expect BED to launch in 1Q15 [] Currently no approved Binge Eating Disorder treatments ------------------------------------------------------------ SHP609 Hunter Sanfilippo SHP610 [] Progressed our intrathecal programs to treat CNS manifestations of Hunter and Sanfilippo A (Phase 2) CNS A ------------------------------------------------------------ [] Reinforced Rare Diseases leadership through internal Rare Diseases research and partnerships while extending this model to Platform new indications and TAs ------------------------------------------------------------ [] Halted programs that did not fit strategic or commercial Rationalization criteria 1 Lisdexamfetamine dimesylate, active ingredient in VYVANSE/ELVANSE. 11

and since March 2013 acquired products with significant peak sales potential [GRAPHIC OMITTED] [] Acquired Lifitegrast in 2Q13 [] 1(st) product to show efficacy for signs and symptoms of Dry Eye Disease [] Plan to file NDA in 1Q15 [] Low volume IV and SC programs for HAE prophylaxis (Phase 1) plus new uses [] Acquired Premacure in 1Q13 [] Novel protein replacement therapy to prevent retinopathy of prematurity (Phase 2) [] Two hepatic assets for our existing GI franchise [] LUM001 for 4 indications in rare liver diseases (Phase 2) [] LUM002 for NASH (Completed Phase 1) [] Acquired as part of ViroPharma [] Treatment of cytomegalovirus infection in transplant patients (Phase 2) [] Adds(1) an anti-fibrotic agent for rare and renal diseases (Phase 1) as well as Fibrotech's library of novel molecules 1 The Fibrotech acquisition has yet to close 12

These initiatives have already had a significant impact on shareholder value Immediate impact Enhanced pipeline Accelerated growth Increased efficiency Focused M&A and licensing Increasing shareholder value [GRAPHIC OMITTED] 1 Sourced from Company reports, S&P Capital IQ (McGraw Hill Financial), 19 June 2014 2 Median of Alexion, Amgen, Biogen, Celgene and Gilead. 13

$10B in product sales by 2020 will come from across our existing In-line and pipeline products In-Line and Pipeline Assets across BUs [GRAPHIC OMITTED] will drive sustainable long-term growth 1 [GRAPHIC OMITTED] 1 The percentages derive from the projected product sales for each business unit as set out in the LRP and have been rounded to the nearest 5%. Forecast growth includes Viropharma product sales (Viropharma was acquired by Shire in January 2014). Further potential upside to this 10x20 target includes the Lumena acquisition, the recently announced Fibrotech transaction and future M&A and licensing. 14

Lifitegrast has blockbuster potential as the 1(st) product to treat the signs and symptoms of Dry Eye Disease [GRAPHIC OMITTED] 1 This represents Shire management's estimate of the potential annual net sales for the product in 2020. This estimate is not risk-adjusted and is made using customary pharmaceutical industry forecasting methods. 15

SHP607 (Premiplex) has the potential to be a 1(st)-in-class treatment for one of the most common causes of childhood vision loss [GRAPHIC OMITTED] 1 This represents Shire management's estimate of the potential annual net sales for the product in 2020. This estimate is not risk-adjusted and is made using customary pharmaceutical industry forecasting methods. 16

SHP465 has the potential to address unmet need in the fast growing adult ADHD segment through additional duration [GRAPHIC OMITTED] 1 This represents Shire management's estimate of the potential annual net sales for the product in 2020. This estimate is not risk-adjusted and is made using customary pharmaceutical industry forecasting methods. 17

Binge Eating Disorder (BED) -- LDX would represent the first approved treatment option for this condition [GRAPHIC OMITTED] 1 This represents Shire management's estimate of the potential annual net sales for the product in 2020. This estimate is not risk-adjusted and is made using customary pharmaceutical industry forecasting methods. 18

Intrathecal programs offer novel treatments to address the CNS manifestations of pediatric lysosomal storage diseases [GRAPHIC OMITTED] 1 This represents Shire management's estimate of the potential annual net sales for the product in 2020. This estimate is not risk-adjusted and is made using customary pharmaceutical industry forecasting methods. 19

Lumena adds further peak sales potential of greater than $3B which has not yet been factored into the LRP(1) [GRAPHIC OMITTED] 1 Peak year sales are Shire management's estimates of the highest annual net sales for the relevant product. These peak year sales estimates are not risk-adjusted, and are made using customary pharmaceutical industry forecasting methods. The peak year sales for LUM001 and LUM002 occur in years later than 2020, but these estimates are consistent with the plans and projections of the LRP period. 20

We aspire to be a world leading biotech Characteristics of leading biotechs Strong growth Highly profitable Leadership in specific Therapeutic Areas Innovative pipelines sourced internally and externally Shareholder returns in excess of the broader market Illustrative peer group(1) [GRAPHIC OMITTED] 1 Not all of the illustrative peers possess each of these characteristics 21

We have assembled a high-performing and cohesive management team[] Recent additions and internal advancements [GRAPHIC OMITTED] 22

with a record of accomplishment [GRAPHIC OMITTED] 23

We are building a leading biotech growth profile Future actions Continue to optimize our existing in-line assets Progress and commercialize our existing pipeline Continue to add assets in our core and adjacent TAs Enhance research platforms to drive long-term growth Leading Biotechs: 2013 YOY Growth [GRAPHIC OMITTED] 1 Sourced from FY2013 earnings releases 24

We intend to drive further efficiencies, to give us flexibility to increase margins or reinvest in growth Future opportunities Operating leverage from a lean and profitable commercial infrastructure Continue to optimize tax base with appropriate planning Ensuring an efficient long-term site footprint Benefits of scale and Therapeutic Area leadership Leading biotech profitability 1,2 [GRAPHIC OMITTED] 1 Sourced from 2013 Annual Reports, Earning Releases and may be prepared and present on the basis of different assumptions and accounting practices. 2 Margins presented as a percent of net product sales 3 Adjusted for revenue from royalties, collaborative agreements, and unconsolidated joint business, and non-GAAP company adjustments as per earnings release statements 4 Biogen Idec has substantial royalty revenues which equates to ~44% adjusted EBITDA margin as a percent of revenue 5 This is a Non-GAAP financial measure. The most directly comparable measure under U.S. GAAP is net income (Q1 2014: $230M or 18% of product sales; FY 2013: $665M or 14% of product sales). See slide 37 for a list of items excluded from the U.S.GAAP equivalent used to calculate this measure. 25

We have built leading positions in commercially attractive therapeutic areas[] [GRAPHIC OMITTED] 1 Seeking Alpha "Dyax And ViroPharma: An Overview Of HAE Space", 18 Sep 2012 2 Lisdexamfetamine dimesylate, active ingredient in VYVANSE / ELVANSE. 3 IMS NPA Weekly Date Reports for week ending 7 February 2014 and Attributable Ranking Study, 2013 26

and are building positions in adjacent therapeutic areas [GRAPHIC OMITTED] 1 Evaluate Pharma "Long Term Outlook: Ocular Antineovascularisation Products and Sensory Organ Category Sales", 18 June 2014 2 Evaluate Pharma "Long Term Outlook: Blood & blood forming malignancies", 18 June 2014 27

We now have an enhanced, innovative pipeline with peak sales potential of greater than $7 billion(1) [GRAPHIC OMITTED] 1 greater than $7B peak sales potential includes products that have completed Phase 1, including those programs acquired with the Lumena acquisition, but excludes lifecycle management programs. 2 SHP611 is currently in a Phase 1/2 clinical trial. 3 Subcutaneous formulation. 4 The Fibrotech acquisition has yet to close 5 Lisdexamfetamine dimesylate, active ingredient in VYVANSE/ELVANSE. 6 SHP602 on clinical hold. 7 SHP610 has completed its Phase 1/2 clinical trial and preparation is underway for a Phase 2b trial. 8 Alagille syndrome (ALGS), Progressive Familial Intrahepatic Cholestasis (PFIC), Primary Biliary Cirrhosis (PBC), and Primary Sclerosing Cholangitis (PSC) 28

We are reinforcing Rare Diseases leadership through internal research and partnerships [] Rare diseases -focused research 90%+ of pre-clinical effort targets rare / orphan indications Existing platforms in enzyme and protein replacement Building new platforms in intrathecal administration and mRNA Refine project selection expertise to identify external opportunities Sample external collaborations [GRAPHIC OMITTED] 29

while actively extending our Rare Diseases model to new indications and therapeutic areas [GRAPHIC OMITTED] 1 SHP610 has completed its Phase 1/2 clinical trial and preparation is underway for a Phase 2b trial. 2 Lisdexamfetamine dimesylate, active ingredient in VYVANSE/ELVANSE. 3 Alagille syndrome (ALGS), Progressive Familial Intrahepatic Cholestasis (PFIC), Primary Biliary Cirrhosis (PBC), and Primary Sclerosing Cholangitis (PSC) 30

We have a focused business development strategy to acquire assets in our core and adjacent TAs [GRAPHIC OMITTED] 31

We have the capabilities and scale to quickly integrate and pay down substantial acquisitions [GRAPHIC OMITTED] 1 Rolling 12 months cash generation and free cash flow, for the 12 months to 31 March 2014. 2 Cash generation and free cash flow are Non-GAAP financial measures. The most comparable measure under U.S. GAAP is net cash provided by operating activities, which for the 12 months to 31 March 2014 was $1,549M. See slide 37 for a list of items excluded from the U.S. GAAP equivalents used to calculate these measures. 32

Our innovative "One Path" program enables us to identify, support and manage Rare Disease patients [GRAPHIC OMITTED] 33

and helps us to address significant unmet needs [GRAPHIC OMITTED] 34

10 x 20: We expect to deliver double -digit growth and $10 billion in product sales from our current portfolio by 2020 Executing our strategy [] Commercial excellence Operational efficiency Leading positions in attractive Therapeutic Areas (TAs) Innovative pipeline with greater than $7 billion in peak sales potential 2 Focused business development to expand core and adjacent TAs Simple structure and high-performing management to drive long-term growth even before additional M&A and in-licensing 1 [GRAPHIC OMITTED] 1 Forecast growth includes ViroPharma product sales (ViroPharma was acquired by Shire in January 2014) but is stated before additional M&A and before the impact of the recently closed Lumena transaction and the recently announced Fibrotech transaction. Growth refers to compound annual product sales growth. 2 greater than $7B peak sales potential includes products that have completed Phase 1, including those programs acquired with the Lumena acquisition, but excludes lifecycle management programs 35

Appendix 36

Non-GAAP measures * This presentation contains financial measures not prepared in accordance with U.S. GAAP. * These Non-GAAP financial measures are used by Shire's management to make operating decisions because they facilitate internal comparisons of the Company's performance to historical results and to competitors' results. They should not be considered in isolation from, as substitutes for, or superior to financial measures prepared in accordance with U.S. GAAP. * The following items are excluded from these Non-GAAP financial measures: * Amortization and asset impairments: * Intangible asset amortization and impairment charges; and* Other than temporary impairment of investments. * Acquisitions and integration activities: * Upfront payments and milestones in respect of in-licensed and acquired products; * Costs associated with acquisitions, including transaction costs, and fair value adjustments on contingent consideration and acquired inventory;* Costs associated with the integration of companies; and* Non-controlling interest in consolidated variable interest entities. * Divestments, re-organizations and discontinued operations: * Gains and losses on the sale of non-core assets; * Costs associated with restructuring and re-organization activities;* Termination costs; and* Income / (losses) from discontinued operations. * Legal and litigation costs: * Net legal costs related to the settlement of litigation, government investigations and other disputes (excluding internal legal team costs). * Cash generation represents net cash provided by operating activities, excluding up-front and milestone payments for in-licensed and acquired products, tax and interest payments. * Free cash flow represents net cash provided by operating activities, excluding up-front and milestone payments for in-licensed and acquired products, but including capital expenditure in the ordinary course of business. * A reconciliation of these Non GAAP financial measures to the most directly comparable measure under U.S. GAAP can be found within the Investor's section on Shire's website at www.shire.com 37

Disclaimer (1/2) The directors of Shire accept responsibility for the information contained in this presentation. To the best of their knowledge and belief, the information contained in this presentation for which they are responsible is in accordance with the facts and does not omit anything likely to affect the import of such information. For the avoidance of doubt, no statement below shall operate to limit or exclude the liability of the directors pursuant to the statements above. This presentation has been prepared by Shire (the "Company") . By attending the meeting where this presentation is made, or by reading the presentation slides, you agree to be bound by the following conditions. This presentation does not constitute or form part of, and should not be construed as: (i) an offer, solicitation or invitation to subscribe for, sell or issue, underwrite or otherwise acquire any securities or financial instruments, nor shall it, or the fact of its communication, form the basis of, or be relied upon in connection with, or act as any inducement to enter into any contract or commitment whatsoever with respect to such securities or financial instruments; or (ii) any form of financial opinion, recommendation or investment advice with respect to any securities or financial instruments. The information and opinions in this presentation are not based upon a consideration of your particular investment objectives, financial situation or needs. You may wish to seek independent legal, regulatory, accounting, tax and such professional advice as appropriate with regards to the contents of this presentation. No person is under any obligation to update, complete, revise or keep current the information contained in this presentation. The information contained in this presentation has not been independently verified and some of the information is still in draft form and no reliance should be placed on such information. No representation, warranty or undertaking, express or implied, is made by Shire, Citi, Deutsche Bank, Evercore, Goldman Sachs, or Morgan Stanley (together, the "Banks") or their respective advisors or representatives or their respective affiliates, officers, employees or agents as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of this presentation. None of the Company, the Banks, nor any of their respective advisors nor representatives or any of their respective affiliates, officers, employees or agents shall have any liability whatsoever (in negligence or otherwise) for any direct or consequential loss, damages, costs or prejudices whatsoever arising from the use of this presentation or its contents or otherwise arising in connection with the presentation. The Company, the Banks and their respective advisors and representatives and their respective affiliates, officers, employees or agents, save with respects to any liability for fraud, expressly disclaim any and all liability whether direct or indirect, express or implied, contractual, tortuous, statutory or otherwise, in connection with the accuracy or completeness of the information or for any of the opinions contained herein or for any errors, omissions or misstatements contained in this presentation. 38

Disclaimer (2/2) This presentation has been provided to you solely for your information and background. It is directed only at persons who: (i) are investment professionals as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order"); or (ii) fall within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc") of the Order (all such persons being "relevant persons") . It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons and may not be relied upon by such persons and is therefore not intended for private individuals. This presentation is only for relevant persons and must not be acted on, reviewed or relied on by persons who are not relevant persons. This presentation is not directed at, or intended for distribution to or use by any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution or use would be contrary to law or regulation or which would require any registration or licensing. This presentation and its contents are confidential and you and your directors, officers, employees, agents and affiliates must hold this presentation and any oral information provided in connection with this presentation in strict confidence. This presentation must not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other person, whether or not such person is a relevant person. If you have received this presentation and you are not relevant person, you must return it immediately to the Company. This presentation does not constitute an offer or solicitation to purchase or subscribe for securities in the United States. The securities to which the presentation relates have not been registered, and will not be registered, under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold in the United States unless they are registered under the U.S. Securities Act or pursuant to an exemption firm, or in a transaction not subject to the registration requirements of the U.S. Securities Act. There will be no public offering of securities in the United States. All trade marks designated [R] and [] used in this press release are trade marks of Shire plc or companies within the Shire group except for DERMAGRAFT[R] which is a trade mark of Organogenesis, Amgen [R] and Biogen Idec [R] (which are trademarks of Amgen and Biogen Idec, respectively) . Certain trade marks of Shire plc or companies within the Shire group are set out in Shire's Annual Report on Form 10-K for the year ended December 31, 2013. 39